Fresenius SE EBITDA 2016-2023 | FSNUY

Fresenius SE EBITDA for the quarter ending September 30, 2023 was $-0.217B, a 113.65% decline year-over-year.

  • Fresenius SE 2022 EBITDA was 6.631B, a 17.87% decline from 2021.
  • Fresenius SE 2021 EBITDA was 8.075B, a 0.44% decline from 2020.
  • Fresenius SE 2020 EBITDA was 8.11B, a 2.24% increase from 2019.

EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.

Fresenius SE EBITDA 2016-2023 | FSNUY

  • Fresenius SE 2022 EBITDA was 6.631B, a 17.87% decline from 2021.
  • Fresenius SE 2021 EBITDA was 8.075B, a 0.44% decline from 2020.
  • Fresenius SE 2020 EBITDA was 8.11B, a 2.24% increase from 2019.

EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
Related Stocks
Company NameMarket
Cap
Quest Diagnostics (DGX)$17.3B
DaVita (DVA)$13.8B
Encompass Health (EHC)$9.2B
Chemed (CHE)$8.7B
Elanco Animal Health (ELAN)$7.1B
Option Care Health (OPCH)$5.3B
RadNet (RDNT)$4.9B
Amedisys (AMED)$3.2B
Astrana Health (ASTH)$2.7B
LifeStance Health (LFST)$2.6B
Addus HomeCare (ADUS)$2.4B
U.S Physical Therapy (USPH)$1.3B
Pennant (PNTG)$1B
Aveanna Healthcare Holdings (AVAH)$1B
Atai Life Sciences (ATAI)$215M
Daxor (DXR)$46M
ATI Physical Therapy (ATIP)$26M
MEDIROM Healthcare Technologies (MRM)$19M
Psychemedics (PMD)$14M
Ontrak (OTRK)$10M
Novo Integrated Sciences (NVOS)$5M
IMAC Holdings (BACK)$2M